6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $8M | -$33M | 0.0% | -469.3% | -$40M | — | $12M |
| 2024 | $8M | -$63M | 0.0% | -949.9% | -$61M | — | $7M |
| 2023 | $8M | -$69M | 0.0% | -967.4% | -$70M | — | $11M |
| 2022 | $6M | -$88M | 0.0% | -1576.6% | -$78M | — | $9M |
| 2021 | $1M | -$99M | 0.0% | -7364.1% | -$59M | — | $27M |
| 2020 | $231000 | -$61M | 0.0% | -21290.9% | -$51M | — | $6M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $26000 | -$7M | 0.0% | -29234.6% | — | — | $12M |
| Dec '25 | $3M | -$7M | 0.0% | -283.4% | -$7M | — | $12M |
| Sep '25 | $2M | -$7M | 0.0% | -355.1% | — | — | $18M |
| Jun '25 | $2M | -$9M | 0.0% | -510.5% | — | — | $10M |
| Mar '25 | $1M | -$11M | 0.0% | -991.4% | — | — | $8M |
| Dec '24 | $0 | -$16M | — | — | -$14M | — | $7M |
| Sep '24 | $1M | -$15M | 0.0% | -1441.1% | -$14M | — | $9M |
| Jun '24 | $1M | -$21M | 0.0% | -1772.3% | -$16M | — | $6M |
| Mar '24 | $5M | -$11M | 0.0% | -324.1% | -$17M | — | $4M |
| Dec '23 | $2M | -$18M | 0.0% | -946.2% | -$14M | — | $11M |
| Sep '23 | $3M | -$16M | 0.0% | -719.3% | -$17M | — | $9M |
| Jun '23 | $1M | -$18M | 0.0% | -1383.9% | -$15M | — | $13M |
| Mar '23 | $2M | -$17M | 0.0% | -1008.5% | -$23M | — | $15M |
| Dec '22 | $1M | -$20M | 0.0% | -1491.1% | -$18M | — | $9M |
| Sep '22 | $2M | -$22M | 0.0% | -1058.0% | -$14M | — | $11M |
| Jun '22 | $1M | -$23M | 0.0% | -1655.3% | -$21M | — | $23M |
| Mar '22 | $813000 | -$24M | 0.0% | -2936.8% | -$25M | — | $44M |
| Dec '21 | $508000 | -$27M | 0.0% | -5329.7% | -$18M | — | $27M |
| Sep '21 | $752000 | -$23M | 0.0% | -3128.5% | -$20M | — | $24M |
| Jun '21 | $0 | -$24M | — | — | -$5M | — | $58M |
How the market has priced BOLT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Bolt Biotherapeutics, Inc.'s revenue has grown 101.6% per year. These are computed facts, not advice.
As of FY2025, Bolt Biotherapeutics, Inc. reported — of total debt against $12M of cash.
In FY2025, gross margin was —, operating margin -469.3%, and net margin -433.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.